Shanghai Pharmaceuticals (SPH), a vertically incorporated Chinese pharmaceutical conglomerate, was bearing in mind its tactical alternatives in the context of a rapidly evolving sector, policy, and economic environment. The company-essentially a collection of subsidiaries operating under a unified management structure-was formed through the 2009 merger of several state-owned enterprises, part of a broad policy attempt in China to streamline state assets, consolidate the fragmented pharmaceutical sector, and improve the worldwide competitiveness of national businesses.
As it contended with other large domestic businesses to turn into few national champs the government expected to create, SPH was also considering an acquisition in the U.S. or Europe. This case enables students to consider the broad tendencies crossing China's pharmaceutical industry and healthcare sector and appraise future chances for domestic and foreign businesses.
Shanghai Pharmaceuticals case study solution
PUBLICATION DATE: September 05, 2012 PRODUCT #: 313016-PDF-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
Cells for Life (B)
Cola Wars Continue: Coke and Pepsi in 2010
Starbucks: Strategy Implementation
Telect Inc. and the 30-Year Ride: Edgy or Over the Edge?
Kevin Bertolini: Stop-Loss Strategy
NephroPlus
Thought Leader Interview: Max Bazerman
The Freelancers Union (A)
BP and the Gulf of Mexico Oil Spill
Freddie Mac: Managing in Conservatorship
